Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Pamela L Mendoza-MunozDepartment of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.ORCID 0000-0002-7416-9875
Narva Deshwar KushwahaDepartment of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA.
Dineshsinha ChauhanDepartment of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA.
Karim Ben Ali GacemInstitute for Integrative Biology of the Cell (I2BC), Institute Joliot, CEA, CNRS, Université Paris-Sud, 91198 Gif-sur-Yvette Cedex, France.
Joy E GarrettDepartment of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Joseph R DynlachtDepartment of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Jean-Baptiste CharbonnierInstitute for Integrative Biology of the Cell (I2BC), Institute Joliot, CEA, CNRS, Université Paris-Sud, 91198 Gif-sur-Yvette Cedex, France.ORCID 0000-0002-5219-1983
Navnath S GavandeDepartment of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA.
John J TurchiDepartment of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.ORCID 0000-0001-5375-2992
Funding
Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI David W Clapp · 1999 to 2026
$59.3M
Discovery and development of Ku-targeted small molecule inhibitors: A novel mechanism of DNA-PK inhibitionR01CA247370 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI Navnath S Gavande, JOHN J. TURCHI · 2020 to 2026
$3.5M
Agence Nationale de la Recherche France ANR-20-CE11-0026, ANR-23-CE11-0033, ANR-23-CE18NCI NIH HHS P30 CA082709NCI NIH HHS R01 CA247370NIH HHS 5R01CA247370-05A1
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
DNA-PKdouble-strand break repairKu-DBisnon-homologous end joiningnon-small cell lung cancersmall-molecule inhibitors
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Impact of Optimized Ku-DNA Binding Inhibitors on the Cellular and In Vivo DNA Damage Response. · full record | OpenQuestion